These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26945263)

  • 1. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia.
    Gadomska G; Stankowska K; Boinska J; Bartoszewska-Kubiak A; Haus O; Rość D
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):817-821. PubMed ID: 26945263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
    Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
    Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
    Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
    Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
    Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia.
    Gadomska G; Ziołkowska K; Boinska J; Filipiak J; Rość D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30781507
    [No Abstract]   [Full Text] [Related]  

  • 6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
    Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
    Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
    Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
    Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.
    De Stefano V; Za T; Rossi E; Fiorini A; Ciminello A; Luzzi C; Chiusolo P; Sica S; Leone G
    Haematologica; 2009 May; 94(5):733-7. PubMed ID: 19336736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-2 V617F mutation increases heparanase procoagulant activity.
    Kogan I; Chap D; Hoffman R; Axelman E; Brenner B; Nadir Y
    Thromb Haemost; 2016 Jan; 115(1):73-80. PubMed ID: 26489695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
    Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
    Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM
    Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the blood coagulation process in patients with essential thrombocythemia.
    Ziołkowska K; Boinska J; Gadomska G; Wieczór R; Rość D
    Blood Coagul Fibrinolysis; 2020 Apr; 31(3):219-224. PubMed ID: 32108679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients.
    Sokołowska B; Nowaczyńska A; Bykowska K; Chocholska S; Wejksza K; Walter-Croneck A; Gromek T; Kowalska AM; Kandefer-Szerszeń M; Dmoszyńska A
    Folia Histochem Cytobiol; 2011; 49(2):267-71. PubMed ID: 21744327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.
    Marchetti M; Tartari CJ; Russo L; Panova-Noeva M; Leuzzi A; Rambaldi A; Finazzi G; Woodhams B; Falanga A
    Am J Hematol; 2014 Jan; 89(1):68-73. PubMed ID: 24009132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.